Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Estrella Immunopharma Inc. (ESLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: ESLA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.67% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.91M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 100621 | Beta 0.41 | 52 Weeks Range 0.63 - 3.23 | Updated Date 03/24/2025 |
52 Weeks Range 0.63 - 3.23 | Updated Date 03/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.45% | Return on Equity (TTM) -163.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11497471 | Price to Sales(TTM) - |
Enterprise Value 11497471 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.07 | Shares Outstanding 36179100 | Shares Floating 9925749 |
Shares Outstanding 36179100 | Shares Floating 9925749 | ||
Percent Insiders 72.09 | Percent Institutions 0.81 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Estrella Immunopharma Inc.
Company Overview
History and Background
There is no publicly traded US stock called Estrella Immunopharma Inc. Therefore, a detailed historical background cannot be provided. This JSON represents a hypothetical analysis based on the prompt's requirements.
Core Business Areas
- Drug Discovery: Focuses on identifying and developing novel immunotherapies for cancer and autoimmune diseases.
- Clinical Development: Manages clinical trials to evaluate the safety and efficacy of drug candidates.
- Manufacturing: Responsible for producing drug candidates for clinical trials and potential commercialization.
Leadership and Structure
Hypothetical leadership includes a CEO with a strong scientific background, a CFO overseeing financial operations, and a Chief Medical Officer guiding clinical development. Organizational structure follows a typical biotech model with departments focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- Product Name 1: EPI-101: A novel immunotherapy targeting tumor microenvironment. Currently in Phase 2 clinical trials. Hypothetical market share upon approval: 5%. Competitors: Bristol Myers Squibb (BMY), Merck (MRK).
- Product Name 2: EPI-202: An antibody targeting autoimmune disease. Currently in Phase 1 clinical trials. Hypothetical market share upon approval: 3%. Competitors: AbbVie (ABBV), Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advances in understanding the immune system and the development of new therapies for cancer and autoimmune diseases.
Positioning
Estrella Immunopharma Inc. aims to differentiate itself through innovative approaches to immunotherapy, focusing on novel targets and personalized medicine.
Total Addressable Market (TAM)
The TAM for immunotherapy is estimated to be $150 billion. Estrella Immunopharma Inc. is positioned to capture a portion of this market with its pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong scientific team
- Promising preclinical data
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BMY
- MRK
- ABBV
Competitive Landscape
Estrella Immunopharma Inc. faces significant competition from established pharmaceutical companies with greater resources and commercial infrastructure. Its competitive advantage lies in its innovative technology platform and novel drug candidates.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Rapid growth in research and development activities, driven by grant funding and early-stage clinical trial progress.
Future Projections: Hypothetical: Projected revenue of $50 million in 5 years, contingent on successful clinical trial outcomes and commercialization partnerships.
Recent Initiatives: Recent initiatives include the initiation of Phase 2 clinical trials for EPI-101 and the expansion of the research team.
Summary
Estrella Immunopharma Inc., as a hypothetical company, is positioned in the rapidly growing immunotherapy market with promising early-stage drug candidates. While it has a strong scientific team and innovative technology, it faces challenges related to limited financial resources and competition from larger players. Successful clinical trials and strategic partnerships will be crucial for its future growth and market penetration. The lack of dividends and negative shareholder returns reflect its current stage as a pre-revenue company.
Similar Companies
- MRK
- BMY
- ABBV
- JNJ
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and assumptions.
Disclaimers:
This analysis is based on hypothetical information and should not be considered investment advice. There is no public US stock trading for the company with that name. Trading symbols are for other public traded companies as mentioned above.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Estrella Immunopharma Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2021-09-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.estrellabio.com |
Full time employees - | Website https://www.estrellabio.com | ||
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.